Senate Budget Deal Seems To Include Part D Offset That Drug Makers Oppose

Drug lobbyists and policy analysts say the Senate budget deal includes a Medicare Part D offset that the brand drug industry strongly opposes, but they say the details of the measures are unclear because they are written in a way that is difficult to decipher. The Senate deal would increase drug companies' share of coverage-gap discounts from 50 percent to 75 percent, and it might also count those discounts toward beneficiary out-of-pocket spending to reduce government spending on catastrophic drug...